Decreased RNA Integrity [PE] - N0000008852

Pharmacologic Code	N0000008852
Pharmacologic Name	Decreased RNA Integrity
Pharmacologic Uses	aminolevulinate synthase 1-directed small interfering RNA antithrombin-directed small interfering ribonucleic acid transthyretin-directed antisense oligonucleotide transthyretin-directed small interfering RNA
Pharmacologic Concept	Physiologic Effects - [PE]
Pharmacologic Concept Description	This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

The table contains 7 products whose active ingredient are classified under the same pharmacologic class Decreased RNA Integrity [PE].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0310-9400	Wainua	Non-Proprietary Name: Eplontersen	Injection, Solution	Subcutaneous	Astrazeneca Pharmaceuticals Lp	ACTIVE
	58468-0347	Qfitlia	Non-Proprietary Name: Fitusiran	Injection, Solution	Subcutaneous	Genzyme Corporation	ACTIVE
	58468-0348	Qfitlia	Non-Proprietary Name: Fitusiran	Injection, Solution	Subcutaneous	Genzyme Corporation	ACTIVE
	71336-1000	Onpattro	Non-Proprietary Name: Patisiran	Injection, Lipid Complex	Intravenous	Alnylam Pharmaceuticals, Inc.	ACTIVE
	71336-1001	Givlaari	Non-Proprietary Name: Givosiran Sodium	Injection, Solution	Subcutaneous	Alnylam Pharmaceuticals, Inc.	ACTIVE
	71336-1003	Amvuttra	Non-Proprietary Name: Vutrisiran	Injection	Subcutaneous	Alnylam Pharmaceuticals, Inc.	ACTIVE
	72126-007	Tegsedi	Non-Proprietary Name: Inotersen	Injection, Solution	Subcutaneous	Akcea Therapeutics, Inc.	ACTIVE